Abstract
Functional naïve T-cells are critical for an effective immune response to multiple pathogens. HIV leads to a significant reduction in CD4+ naïve T-cell number and impaired function and there is incomplete recovery following combination antiretroviral therapy (cART). Here we review the basic homeostatic mechanisms that maintain naïve CD4+ T-cells and discuss recent developments in understanding the impact of HIV infection on naïve CD4+ T-cells. Finally we review therapeutic interventions in HIV-infected individuals aimed at specifically enhancing recovery of naïve CD4+ T-cells.
Copyright © 2011 Elsevier Inc. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Anti-HIV Agents / therapeutic use
-
CD4 Lymphocyte Count
-
CD4-Positive T-Lymphocytes / immunology*
-
CD4-Positive T-Lymphocytes / virology
-
Chemokines / immunology
-
Clinical Trials as Topic
-
Dendritic Cells / immunology
-
Dendritic Cells / virology
-
HIV Infections / drug therapy
-
HIV Infections / immunology*
-
HIV Infections / virology
-
HIV-1 / immunology*
-
Humans
-
Interleukin-2 / immunology
-
Interleukin-2 / therapeutic use
-
Interleukin-7 / immunology
-
Interleukin-7 / therapeutic use
-
Mice
-
Receptors, Antigen, T-Cell / immunology
-
Receptors, Interleukin-7 / immunology
Substances
-
Anti-HIV Agents
-
Chemokines
-
Interleukin-2
-
Interleukin-7
-
Receptors, Antigen, T-Cell
-
Receptors, Interleukin-7